Dutasteride

Dutasteride (Avodart) is a synthetic 4-azasteroid that inhibits both Type I (SRD5A1) and Type II (SRD5A2) isoforms of 5α-reductase. The dual inhibition produces more complete suppression of testosterone-to-DHT conversion than finasteride’s Type II selective action, supporting stronger hair-retention efficacy at proportional side-effect risk.

Mechanism — dual isoform inhibition:

Finasteride is Type II selective with minimal Type I activity. Dutasteride binds both isoforms with high affinity. The clinical impact: serum DHT reduction approximately 95% on dutasteride vs 70% on finasteride; scalp DHT reduction 90% vs 60–70%. The additional Type I inhibition matters because Type I expression in scalp follicles, while smaller than Type II, contributes meaningful residual DHT conversion that finasteride leaves unaddressed.

Clinical evidence — head-to-head superiority:

Olsen et al. 2006, J Am Acad Dermatol directly compared dutasteride 0.5 mg/day vs finasteride 1 mg/day vs placebo in men with androgenic alopecia. Dutasteride produced superior vertex hair count change at 24 weeks. The effect size difference is modest in absolute terms but statistically significant and clinically meaningful for users with progressive hair loss.

The comparator data has implications for protocol selection: finasteride non-responders frequently respond to dutasteride; users with aggressive familial-pattern alopecia genetically predicted to lose hair despite finasteride may benefit from dutasteride initial choice.

Pharmacokinetics — the long-half-life characteristic:

Dutasteride elimination half-life is approximately 5 weeks at steady-state — substantially longer than finasteride’s 6–8 hours. The kinetic supports practical dosing flexibility:

– Standard daily dose: 0.5 mg orally
– Once tissue saturation is reached (~5 weeks of daily dosing), every-other-day dosing maintains adequate suppression
– Some users dose 3 times per week long-term with comparable efficacy at one-quarter the cumulative drug exposure
– The long half-life also means side-effect onset and resolution are slower than finasteride; titration decisions require longer observation windows

BPH indication and AAS-protocol use:

Dutasteride is FDA-approved for benign prostatic hyperplasia at 0.5 mg/day. Off-label use for androgenic alopecia is widespread; off-label use for AAS-protocol scalp protection follows the same dosing.

– Cycle harm-reduction protocol: start 2 weeks before AAS cycle initiation through PCT completion
– Continuous use post-cycle for users with established hair loss and ongoing protective need
– Combination with topical minoxidil 5% twice daily for additive mechanistic protection

Same mechanism limitation as finasteride:

Dutasteride does not protect against compounds that ARE DHT-derivatives or that bypass 5α-reductase. Trenbolone, drostanolone, stanozolol, oxandrolone, methenolone — all directly active at scalp AR, all unaffected by 5α-reductase inhibition regardless of isoform coverage. For cycles dominated by these compounds, dutasteride is pharmacologically irrelevant for scalp protection.

Nandrolone protocols: same paradoxical concern as finasteride. Blocking 5α-reductase prevents nandrolone-to-DHN conversion (where DHN is a weaker androgen than nandrolone parent), leaving parent nandrolone available for AR binding. Avoid dutasteride during nandrolone-containing cycles.

Side-effect profile — quantitatively similar to finasteride:

The more complete DHT suppression theoretically increases risk of mood and libido effects, though comparative trials show only modest differences. Most documented side effects:

– Sexual: libido reduction, erectile dysfunction, ejaculate volume reduction in 2–8% of users; comparable rates to finasteride in most direct comparisons
– Mood: depression, anxiety in a subset of users via central neurosteroid pathway disruption (5α-reductase metabolises progesterone to allopregnanolone, a positive GABA-A modulator; suppression reduces this)
– Gynaecomastia: rare but documented; mechanism involves estrogen-DHT ratio shift
– Post-discontinuation syndrome: documented but uncommon; the long half-life means side effects may persist longer after stopping than with finasteride

PSA monitoring on dutasteride:

Like finasteride, dutasteride suppresses serum PSA approximately 50%. Prostate cancer screening on dutasteride requires correction (multiply measured PSA by 2). PSA velocity monitoring matters more than absolute values; rising trend warrants urology workup regardless of suppressed baseline.

Practical decision framework — finasteride vs dutasteride:

– First-line for routine androgenic alopecia: finasteride 1 mg/day
– Inadequate response after 6–12 months: switch to dutasteride 0.5 mg/day
– Aggressive family-pattern alopecia at young age: dutasteride initial choice defensible
– High-dose testosterone protocols generating substantial DHT substrate: dutasteride more thorough
– Concern about side effects: try finasteride 0.5 mg/day first (lower dose, lower side-effect rate, ~75% of efficacy)
– Both compounds have the same mechanism limitations on DHT-derivative AAS — the choice between them does not affect protection against trenbolone, masteron, or DHT-class orals.

The clinical question is rarely “finasteride or nothing” or “dutasteride or nothing” — it is “which level of 5α-reductase inhibition matches the user’s hair-loss progression rate, side-effect tolerance, and cycle compound profile.”